{"product_id":"m18678","title":"SB-649868","description":"\u003cp style=\"padding-left: 1em;\"\u003eSB-649868 is a potent and selective orally active orexin (OX) 1 and OX2 receptor antagonist (pKi =9.4 and 9.5 at the OX1 and OX2 receptor, respectively).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eProduct information\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCAS Number:\u003c\/strong\u003e 380899-24-1\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 477.55\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFormula:\u003c\/strong\u003e C26H24FN3O3S\u003c\/p\u003e\n\u003cp style=\"text-indent: -1em; padding-left: 1em;\"\u003e\u003cstrong\u003eChemical Name:\u003c\/strong\u003e N-{[(2S)-1-[5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]piperidin-2-yl]methyl}-1-benzofuran-4-carboxamide\u003c\/p\u003e\n\u003cp style=\"text-indent: -1em; padding-left: 1em;\"\u003e\u003cstrong\u003eSmiles:\u003c\/strong\u003e CC1=NC(=C(S1)C1C=CC(F)=CC=1)C(=O)N1CCCC[C@H]1CNC(=O)C1=CC=CC2OC=CC=21\u003c\/p\u003e\n\u003cp style=\"text-indent: -1em; padding-left: 1em;\"\u003e\u003cstrong\u003eInChiKey:\u003c\/strong\u003e ZJXIUGNEAIHSBI-IBGZPJMESA-N\u003c\/p\u003e\n\u003cp style=\"text-indent: -1em; padding-left: 1em;\"\u003e\u003cstrong\u003eInChi:\u003c\/strong\u003e InChI=1S\/C26H24FN3O3S\/c1-16-29-23(24(34-16)17-8-10-18(27)11-9-17)26(32)30-13-3-2-5-19(30)15-28-25(31)21-6-4-7-22-20(21)12-14-33-22\/h4,6-12,14,19H,2-3,5,13,15H2,1H3,(H,28,31)\/t19-\/m0\/s1\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTechnical Data\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAppearance:\u003c\/strong\u003e Solid Power\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePurity:\u003c\/strong\u003e ≥98% (or refer to the Certificate of Analysis)\u003c\/p\u003e\n\u003cp style=\"text-indent: -1em; padding-left: 1em;\"\u003e\u003cstrong\u003eSolubility:\u003c\/strong\u003e DMSO : 100 mg\/mL (209.40 mM; Need ultrasonic).\u003c\/p\u003e\n\u003cp style=\"text-indent: -1em; padding-left: 1em;\"\u003e\u003cstrong\u003eShipping Condition:\u003c\/strong\u003e Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis\u003c\/p\u003e\n\u003cp style=\"text-indent: -1em; padding-left: 1em;\"\u003e\u003cstrong\u003eStorage Condition:\u003c\/strong\u003e Dry, dark and -20 \u003csup\u003eo\u003c\/sup\u003eC for 1 year or refer to the Certificate of Analysis.\u003c\/p\u003e\n\u003cp style=\"text-indent: -1em; padding-left: 1em;\"\u003e\u003cstrong\u003eShelf Life:\u003c\/strong\u003e ≥12 months if stored properly.\u003c\/p\u003e\n\u003cp style=\"text-indent: -1em; padding-left: 1em;\"\u003e\u003cstrong\u003eStock Solution Storage:\u003c\/strong\u003e 0 - 4 \u003csup\u003eo\u003c\/sup\u003eC for 1 month or refer to the Certificate of Analysis.\u003c\/p\u003e\n\u003cp style=\"text-indent: -1em; padding-left: 1em;\"\u003e\u003cstrong\u003eDrug Formulation:\u003c\/strong\u003e To be determined\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHS Tariff Code:\u003c\/strong\u003e 382200\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHow to use\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIn Vitro:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"padding-left: 1em;\"\u003eSB-649868 is identified as one the most in vitro potent dual OX1 and OX2 receptor antagonist known at that time (pKi=9.4 and 9.5 at the OX1 and OX2 receptor, respectively) . SB-649868 antagonizes orexin-A-induced inositol 1 phosphate (IP1) accumulation with the following pKB value (OX1=9.67; OX2=9.64). SB-649868 displaces the [3H]ACT-078573 receptor binding with the following pKi values: OX1=9.27; OX2=8.91. Increasing concentrations of SB-649868 (0.3 nM-30 nM) induces a rightward shift of the orexin-A CRCs with a depression of the agonist efficacy suggesting a clear non-surmountable behavior. The calculated apparent pKb values are 9.67±0.03 and 9.64±0.07 for OX1 and OX2.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIn Vivo:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"padding-left: 1em;\"\u003ePharmacokinetic studies in the male CD rat, performed at 1 mg\/kg, iv and 3 mg\/kg, po, demonstrate an excellent pharmacokinetic profile for a hypnotic agent featuring moderate clearance in plasma (Clp=24 mL\/min\/kg), short half-life of (\u0026lt;0.6 h) and a low volume of distribution (Vss=1.1 l\/kg), coupled with excellent oral bioavailability (F=85%) and good exposure in plasma (Cmax=333 ng\/mL). A brain to blood ratio (B\/B) of 0.1:1 is observed 1 h after iv administration, a value in line with the expected partition between the two compartments based on the lower tissue binding observed in vitro in brain tissues (fraction unbound\/brain=5.28%) with respect to plasma proteins (fraction unbound\/plasma=1.34%). SB-649868, administered orally 3 h before OX-A injection at doses of 1, 3 and 10 mg\/kg, causes a dose-dependent reduction of OX-A induced grooming as measured by total time spent grooming and number of grooming bouts (p \u0026lt;0.01 at 3 and 10 mg\/kg po) . From dissociation kinetic studies using [3H]ACT-078573, the calculated long half-life, (t1\/2) supports the non-surmountability profile of SB-649868 (t1\/2=35.91 min) at OX1 orexin receptor. The long or moderately long t1\/2values for SB-649868 at OX2 orexin receptor (t1\/2=8.09 min).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eProducts are for research use only. Not for human use.\u003c\/strong\u003e\u003c\/p\u003e","brand":"Xcess Biosciences","offers":[{"title":"M18678-C \/ Contact sales@xcessbio.com for quotation","offer_id":39523092005003,"sku":"0","price":100.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0389\/1897\/9723\/files\/1686561042636.png?v=1686561064","url":"https:\/\/www.xcessbio.com\/products\/m18678","provider":"Xcess Biosciences","version":"1.0","type":"link"}